Latest news
How Investors May Respond To Nurix Therapeutics (NRIX) Advancing Bexobrutideg Into Registrational Phase 3 With Roche - simplywall.stsimplywall.st · Wed, 05 Aug 2026 20:38:08 GMTNurix Phase 3 Trial Tests Bexobrutideg Against CLL Standard of Care - Stock TitanStock Titan · Tue, 04 Aug 2026 05:03:02 GMTNRIX Q2 2026 Earnings: Wider-than-Expected Loss Pressures Shares - EBITDA Analysis - dars.gov.etdars.gov.et · Sat, 01 Aug 2026 09:36:37 GMT